Search results for "Steatosi"

showing 10 items of 261 documents

Hepatic Steatosis Index in Acromegaly: Correlation with Insulin Resistance Regardless of the Disease Control

2018

Objective. In acromegaly, both lipotoxicity secondary to GH excess and insulin resistance have a significant impact on the liver. Ultrasonography has shown poor sensitivity in detecting hepatic steatosis and noninvasive methods have been proposed. We evaluated the hepatic steatosis index (HSI), a validated surrogate index of hepatic steatosis, and we correlated it with disease activity and insulin resistance. Design. Thirty-one patients with newly diagnosed acromegaly were studied at diagnosis and after 12 months of treatment with somatostatin receptor ligands. Methods. Glucose and insulin levels, surrogate estimates of insulin sensitivity, and hepatic steatosis through ultrasonography and …

0301 basic medicinemedicine.medical_specialtyArticle SubjectEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismGastroenterologylcsh:Diseases of the endocrine glands. Clinical endocrinologySettore MED/13 - EndocrinologiaCorrelation03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistanceInternal medicineAcromegalymedicinelcsh:RC648-665Endocrine and Autonomic SystemsSomatostatin receptorbusiness.industryhepatic steatosisInsulinmedicine.diseaseDisease control030104 developmental biologyLipotoxicitySteatosisbusinessResearch ArticleInternational Journal of Endocrinology
researchProduct

Loss of c-Met signaling sensitizes hepatocytes to lipotoxicity and induces cholestatic liver damage by aggravating oxidative stress.

2016

Recent studies confirmed a critical importance of c-Met signaling for liver regeneration by modulating redox balance. Here we used liver-specific conditional knockout mice (MetKO) and a nutritional model of hepatic steatosis to address the role of c-Met in cholesterol-mediated liver toxicity. Liver injury was assessed by histopathology and plasma enzymes levels. Global transcriptomic changes were examined by gene expression microarray, and key molecules involved in liver damage and lipid homeostasis were evaluated by Western blotting. Loss of c-Met signaling amplified the extent of liver injury in MetKO mice fed with high-cholesterol diet for 30days as evidenced by upregulation of liver enz…

0301 basic medicinemedicine.medical_specialtyCell SurvivalCholestasis IntrahepaticBiologyToxicologymedicine.disease_causeArticleCholesterol Dietary03 medical and health sciencesMice0302 clinical medicineLiver Function TestsInternal medicinemedicineAnimalsLiver X receptorLiver injuryMice Knockoutmedicine.diagnostic_testLipid metabolismProto-Oncogene Proteins c-metmedicine.diseaseLipid MetabolismGlutathioneLipidsLiver regenerationOxidative Stress030104 developmental biologyEndocrinologyLipotoxicity030220 oncology & carcinogenesisHepatocytesLipid PeroxidationSteatosisLiver function testsOxidative stressSignal TransductionToxicology
researchProduct

Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors.

2016

Background & Aims The pathomechanisms underlying non-alcoholic fatty liver disease (NAFLD) and the involved molecular regulators are incompletely explored. The nuclear factor-kappa B (NF-κB)-cofactor gene B cell leukemia-3 ( Bcl-3 ) plays a critical role in altering the transcriptional capacity of NF-κB – a key inducer of inflammation – but also of genes involved in cellular energy metabolism. Methods To define the role of Bcl-3 in non-alcoholic steatohepatitis (NASH), we developed a novel transgenic mouse model with hepatocyte-specific overexpression of Bcl-3 ( Bcl-3 Hep ) and employed a high-fat, high-carbohydrate dietary feeding model. To characterize the transgenic model, deep RNA seque…

0301 basic medicinemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentBiology03 medical and health sciencesLiver diseaseMice0302 clinical medicineB-Cell Lymphoma 3 ProteinInternal medicineProto-Oncogene ProteinsmedicineAnimalsHumansInsulinInflammationHepatologyInsulinLiver cellFatty liverLiver Neoplasmsmedicine.disease030104 developmental biologyEndocrinology030220 oncology & carcinogenesisLipogenesisSteatohepatitisSteatosisTranscription FactorsJournal of hepatology
researchProduct

2017

Background and aims Nonalcoholic fatty liver disease is epidemiologically associated with hepatic and metabolic disorders. The aim of this study was to examine whether hepatic fat accumulation has a causal role in determining liver damage and insulin resistance. Methods We performed a Mendelian randomization analysis using risk alleles in PNPLA3, TM6SF2, GCKR and MBOAT7, and a polygenic risk score for hepatic fat, as instruments. We evaluated complementary cohorts of at-risk individuals and individuals from the general population: 1515 from the liver biopsy cohort (LBC), 3329 from the Swedish Obese Subjects Study (SOS) and 4570 from the population-based Dallas Heart Study (DHS). Results Hep…

0301 basic medicinemedicine.medical_specialtyCirrhosismedicine.diagnostic_testbusiness.industryFatty livermedicine.diseaseChronic liver disease3. Good health03 medical and health sciencesLiver disease030104 developmental biology0302 clinical medicineEndocrinologyInsulin resistanceLiver biopsyInternal medicineNonalcoholic fatty liver diseaseInternal MedicineMedicine030211 gastroenterology & hepatologySteatosisbusinessJournal of Internal Medicine
researchProduct

Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial

2017

Background Limited prospective studies have examined changes in non-alcoholic fatty-liver disease (NAFLD) related serum-metabolites and none the effects of NAFLD-reversion. We aimed to evaluate whether perturbations in metabolites indicate predisposition to NAFLD development and to assess the effects of NAFLD reversion on metabolite profiles. Methods A targeted liquid-chromatography tandem mass-spectrometry metabolic profiling (n = 453 metabolites) approach was applied, using serum from 45 subjects of the PREDIMED study, at baseline and after a median 3.8-year follow-up. NAFLD was determined using the hepatic steatosis index; with three groups classified and studied: Group 1, not characteri…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismMetaboliteMedicine (miscellaneous)lcsh:TX341-641Clinical nutritionBiology03 medical and health scienceschemistry.chemical_compoundFetge--MalaltiesInternal medicineLipid biosynthesisHepatic lipotoxicitymedicineMetabolomicsProspective cohort studylcsh:RC620-627Nutrition and DieteticsFatty acid metabolismResearchFatty livernutritional and metabolic diseasesmedicine.diseasedigestive system diseaseslcsh:Nutritional diseases. Deficiency diseases030104 developmental biologyEndocrinologychemistryLipotoxicityFatty acid metabolismSteatosislcsh:Nutrition. Foods and food supplyNon-alcoholic fatty liver diseaseNutrition & Metabolism
researchProduct

Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imb…

2016

Gut microbiota is involved in obesity, metabolic syndrome and the progression of nonalcoholic fatty liver disease (NAFLD). It has been recently suggested that the flavonoid quercetin may have the ability to modulate the intestinal microbiota composition, suggesting a prebiotic capacity which highlights a great therapeutic potential in NAFLD. The present study aims to investigate benefits of experimental treatment with quercetin on gut microbial balance and related gut-liver axis activation in a nutritional animal model of NAFLD associated to obesity. C57BL/6J mice were challenged with high fat diet (HFD) supplemented or not with quercetin for 16 weeks. HFD induced obesity, metabolic syndrom…

0301 basic medicinemedicine.medical_specialtyGut floraDiet High-FatBiochemistryMice03 medical and health sciencesNon-alcoholic Fatty Liver DiseasePhysiology (medical)Internal medicineNonalcoholic fatty liver diseasemedicineAnimalsHumansObesityMetabolic SyndromebiologyFatty liverLipid metabolismLipid Metabolismmedicine.diseasebiology.organism_classificationGastrointestinal MicrobiomeIntestinesToll-Like Receptor 4Disease Models Animal030104 developmental biologyEndocrinologyLiverLipotoxicityImmunologyQuercetinInsulin ResistanceSteatosisMetabolic syndromeDysbiosisSignal TransductionFree Radical Biology and Medicine
researchProduct

Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nona…

2017

Abstract Aims: Nonalcoholic steatohepatitis (NASH) is characterized by steatosis, panlobular inflammation, liver fibrosis, and increased cardiovascular mortality. Dipeptidyl peptidase-4 inhibitors (gliptins) are indirect glucagon-like peptide 1 agonists with antidiabetic and anti-inflammatory activity, used for the treatment of type 2 diabetes. Their potential and underlying mechanisms to treat metabolic liver inflammation and fibrosis as well as the associated vascular dysfunction remain to be explored. Results: In the methionine/choline-deficient (MCD) diet and Mdr2−/− models of NASH and liver fibrosis, treatment with sitagliptin and linagliptin significantly decreased parameters of steat…

0301 basic medicinemedicine.medical_specialtyPhysiologyClinical BiochemistryAnti-Inflammatory AgentsGene ExpressionInflammationType 2 diabetes030204 cardiovascular system & hematologymedicine.disease_causeBiochemistryAntioxidantsProinflammatory cytokineMice03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisInternal medicinemedicineAnimalsMyeloid CellsMolecular BiologyDipeptidyl peptidase-4General Environmental ScienceInflammationMice KnockoutDipeptidyl-Peptidase IV Inhibitorsbusiness.industryMacrophagesCell BiologyMacrophage Activationmedicine.diseaseFibrosisDietDisease Models AnimalOxidative Stress030104 developmental biologyEndocrinologyLiverNADPH Oxidase 2General Earth and Planetary SciencesTumor necrosis factor alphaSteatosismedicine.symptomReactive Oxygen SpeciesbusinessBiomarkersOxidative stressAntioxidants & Redox Signaling
researchProduct

NUPR1 protects liver from lipotoxic injury by improving the endoplasmic reticulum stress response

2021

AbstractBackground and AimsNon-alcoholic fatty liver disease and related hepatic syndromes affect up to one third of the adult population. The molecular mechanisms underlying NAFL etiology remain elusive. Nuclear Protein 1 (NUPR1) expression increases upon cell injury in all organs and recently we report its active participation in the activation of the Unfolded Protein Response (UPR). The UPR typically maintains protein homeostasis, but downstream mediators of the pathway regulate metabolic functions, including lipid metabolism. NUPR1 and UPR increase have been reported in obesity and liver pathologies and the goal of this study was to investigate the roles of NUPR1 in this context.Methods…

0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaPPAR-a signalling UPRPeroxisome proliferator-activated receptorContext (language use)UPRDiet High-FatBiochemistry03 medical and health sciencesLiver diseaseMice0302 clinical medicineInternal medicineCell Line TumorGeneticsmedicineBasic Helix-Loop-Helix Transcription FactorsAnimalsHomeostasisHumansMolecular Biologychemistry.chemical_classificationbusiness.industryEndoplasmic reticulumFatty liverNASHLipid metabolismlipotoxicitymedicine.diseaseEndoplasmic Reticulum StressLipid MetabolismNeoplasm Proteins030104 developmental biologyEndocrinologychemistryLipotoxicityLiverNAFLKnockout mouseUnfolded protein responseUnfolded Protein ResponsePPAR-a signallingSteatosisSteatohepatitisbusiness030217 neurology & neurosurgeryNUPR1Biotechnology
researchProduct

Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nona…

2018

Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver damage and has a strong genetic component. The rs4841132 G>A variant, modulating the expression of protein phosphatase 1 regulatory subunit 3B (PPP1R3B), which is involved in glycogen synthesis, has been reported to reduce the risk of NAFLD but at the same time may favor liver disease by facilitating glycogen accumulation. The aim of this study was to assess the impact of rs4841132 on development of histologic steatosis and fibrosis in 1,388 European individuals in a liver biopsy cohort, on NAFLD hepatocellular carcinoma in a cross-sectional Italian cohort (n = 132 cases), and on liver disease at the population level in the …

0301 basic medicinemedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAPopulation03 medical and health sciencesLiver disease0302 clinical medicineLipid oxidationFibrosisInternal medicineNonalcoholic fatty liver diseasemedicineeducationNASH NAFLDeducation.field_of_studyHepatologymedicine.diagnostic_testbusiness.industryOriginal ArticlesHepatologymedicine.diseasen/a030104 developmental biologyEndocrinologyLiver biopsy030211 gastroenterology & hepatologyOriginal ArticleSteatosisbusiness
researchProduct

2020

Understanding the importance of the gut microbiota (GM) in non-alcoholic fatty liver disease (NAFLD) has raised the hope for therapeutic microbes. We have shown that high hepatic fat content associated with low abundance of Faecalibacterium prausnitzii in humans and, further, the administration of F. prausnitzii prevented NAFLD in mice. Here, we aimed at targeting F. prausnitzii by prebiotic xylo-oligosaccharides (XOS) to treat NAFLD. First, the effect of XOS on F. prausnitzii growth was assessed in vitro. Then, XOS was supplemented or not with high (HFD, 60% of energy from fat) or low (LFD) fat diet for 12 weeks in Wistar rats (n = 10/group). XOS increased F. prausnitzii growth, having onl…

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentFaecalibacterium prausnitziiButyrateGut floradigestive system03 medical and health sciences0302 clinical medicineInternal medicinemedicinechemistry.chemical_classificationNutrition and DieteticsbiologyPrebioticFatty liverfood and beveragesnutritional and metabolic diseasesFatty acidmedicine.diseasebiology.organism_classification3. Good health030104 developmental biologyEndocrinologychemistry030211 gastroenterology & hepatologySteatosisSteatohepatitisFood ScienceNutrients
researchProduct